Continuous and intermittent sibutramine were equally effective at 44 weeks for reducing weight in obese persons

Cheskin, Lawrence J.
March 2002
ACP Journal Club;Mar/Apr2002, Vol. 136 Issue 2, p49
Academic Journal
Presents information on a study which examined the effectiveness of sibutramine for reducing weight in obese patients. Methodology of the study; Results; Comments on the study.


Related Articles

  • New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy. Jinhwa Lee; Kwang-Seop Song; Jahyo Kang; Suk Ho Lee; Junwon Lee // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p564 

    The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe,...

  • Intragastric Balloon in Association with Lifestyle and/or Pharmacotherapy in the Long-Term Management of Obesity. Farina, Maria; Baratta, Roberto; Nigro, Angela; Vinciguerra, Federica; Puglisi, Concetta; Schembri, Roberto; Virgilio, Clara; Vigneri, Riccardo; Frittitta, Lucia // Obesity Surgery;Apr2012, Vol. 22 Issue 4, p565 

    Background: Intragastric balloon (BioEnterics Intragastric Balloon, BIB®) or pharmacotherapy are possible options for the treatment of obese patients when traditional approaches have failed. The aim of our study was to compare in obese patients the effect on weight loss and metabolic changes...

  • Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet–exercise intervention. Bérubé-Parent, S; Prud'homme, D; St-Pierre, S; Doucet, E; Tremblay, A // International Journal of Obesity & Related Metabolic Disorders;Aug2001, Vol. 25 Issue 8, p1144 

    OBJECTIVE: Sibutramine favors a negative energy balance and also has the potential to increase heart rate and blood pressure. We investigated if a progressive supervised sibutramine-diet-exercise clinical intervention could increase the body weight loss previously reported while minimizing the...

  • A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. Suplicy, H; Boguszewski, C L; dos Santos, C M C; do Desterro de Figueiredo, M; Cunha, D R; Radominski, R // International Journal of Obesity;Aug2014, Vol. 38 Issue 8, p1097 

    Context:No long-term studies have compared centrally acting drugs for treating obesity.Objective:To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss.Design and Setting:A prospective,...

  • Weight-Loss Pharmacotherapy: A Brief Review. Huizinga, Mary Margaret // Clinical Diabetes;Fall2007, Vol. 25 Issue 4, p135 

    The article reviews current pharmacological options for weight loss and provides a brief synopsis of potential future options. It says that the medical treatment of obesity is aimed at decreasing appetite, alterating absorption of calories and increasing thermogenesis. It states that the two...

  • Anti-obesity Agents: A Focused Review on the Structural Classification of Therapeutic Entities. Sangmi Oh; Koon Soon Kim; Young Sun Chung; Minho Shong; Seung Bum Park // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p466 

    In addition to its enormous impacts on an individual's quality of life, obesity is a daunting health problem in the world today and the increasing rate of obesity is now causing a severe burden on health care systems. Fortunately, the normalization or reduction of increased body fat reverses the...

  • Treating Obesity: Pharmacology of Energy Expenditure. Clapham, John C. // Current Drug Targets;Apr2004, Vol. 5 Issue 3, p309 

    The pharmacological treatment options for obesity are currently very limited but the prevalence of the disease is increasing rapidly. Obesity has many serious sequelae, the most common of which is type-2-diabetes. The benefits of weight loss on health are established but the major impediment to...

  • Pharmacotherapy of Obesity: An Update. Schurgin, Sunita; Siegel, Richard D. // Nutrition in Clinical Care;Jan-Apr2003, Vol. 6 Issue 1, p27 

    There has been an epidemic of obesity in the last decade, In spite of the rising numbers of people who are overweight and obese, medical treatment of obesity is currently where medical treatment of hypertension was in the 1950s with only two Food and Drug Administration-approved medications for...

  • Safety of drug therapies used for weight loss and treatment of obesity. Ioannides-Demos, Lisa L.; Proietto, Joseph; Tonkin, Andrew M.; McNeil, John J. // Drug Safety;2006, Vol. 29 Issue 4, p277 

    Some of the medications used for weight loss in the management of obesity have been associated with unacceptable morbidity and mortality. Safety concerns have led to the withdrawal of aminorex, followed by the fenfluramines in 1997, and phenylpropanolamine (norephedrine) in 2000. Aminorex was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics